Endocrinology, Vol 129, 1559-1567, Copyright © 1991 by Endocrine Society

ARTICLES

The heterogeneity of human chorionic gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG

LA Cole, A Kardana, P Andrade-Gordon, MA Gawinowicz, JC Morris, ER Bergert, J O'Connor and S Birken
Yale University, New Haven, Connecticut 06510.

Nicks, or missing peptide linkages, have been found in hCG beta-subunit between residues 44 and 45 and between residues 47 and 48. We examined the occurrence and biological and immunological activities of nicked hCG. As shown by sequence analysis, CR127 standard hCG is approximately 20% nicked, half at beta 44-45 and half at beta 47-48. Treatment with human leukocyte elastase increased the extent of nicking of CR127 standard hCG. The longer the incubation of CR127 standard with human leukocyte elastase (0, 2, and 21 h), the greater the extent of nicked hCG (20%, 46%, and 89%). As the extent of nicking increased, the receptor-binding ability diminished, as did the ability to stimulate progesterone production by rat corpus luteal cells in vitro (0.9, 0.74, and 0.29 microgram/microgram hCG, respectively). In a regression analysis, a linear relationship was indicated between the extent of nicking and receptor binding values (97% correlation) and between the extent of nicking and steroidogenic activity in vitro (99% correlation). From the intercepts of the regression lines, it was estimated that nicks reduced receptor binding by 11-fold and reduced the steroidogenic activity of hCG by 5-fold. We examined eight individual hCG preparations, three purified from pregnancy urine, three from urine from patients with hydatidiform mole, and two from urine from women with choriocarcinoma. In descending order, the eight individual hCG preparations were 100%, 100%, 85%, 76%, 42%, 41%, 0%, and 0% intact. Although no correlation was observed between the percent intact and the ability of the eight individual samples to displace 50% [125I]hCG in binding CG/LH receptor (r less than 0.5), a close correlation was noted between the percent intact and the steroidogenic activity in vitro (98% correlation). This separated the effects of nicking on receptor binding and steroidogenic activities and indicated that while multiple factors influence receptor binding, only nicking suppresses the steroidogenic activity of bound hCG. We examined the recognition of nicked hCG molecules by different hCG immunoassays. The Hybritech Tandem assay measured total hCG and did not distinguish nicked and intact hCG molecules (in a regression analysis, immunoactivity vs. percent intact hCG, r less than 0.5). In contrast, the immunometric assay using B109 hCG dimer-specific monoclonal antibody and anti-beta-peroxidase only detected the intact component of hCG (in a regression analysis, immunoreactivity vs. percent intact hCG, 98% correlation). We used these assays together to estimate the percentage of intact hCG and to deduce the extent of nicking.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				K. Handschuh, J. Guibourdenche, V. Tsatsaris, M. Guesnon, I. Laurendeau, D. Evain-Brion, and T. Fournier Human Chorionic Gonadotropin Produced by the Invasive Trophoblast But Not the Villous Trophoblast Promotes Cell Invasion and Is Down-Regulated by Peroxisome Proliferator-Activated Receptor-{gamma} Endocrinology, October 1, 2007; 148(10): 5011 - 5019. [Abstract] [Full Text] [PDF]

				L. Valmu, H. Alfthan, K. Hotakainen, S. Birken, and U.-H. Stenman Site-specific glycan analysis of human chorionic gonadotropin {beta}-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry Glycobiology, December 1, 2006; 16(12): 1207 - 1218. [Abstract] [Full Text] [PDF]

				L. A. Cole, J. M. Sutton, T. N. Higgins, and G. S. Cembrowski Between-Method Variation in Human Chorionic Gonadotropin Test Results Clin. Chem., May 1, 2004; 50(5): 874 - 882. [Abstract] [Full Text] [PDF]

				S. A. Butler and R. K. Iles Ectopic Human Chorionic Gonadotropin {beta} Secretion by Epithelial Tumors and Human Chorionic Gonadotropin {beta}-Induced Apoptosis in Kaposi's Sarcoma: Is There a Connection? Clin. Cancer Res., October 15, 2003; 9(13): 4666 - 4673. [Abstract] [Full Text] [PDF]

				S. Birken, P. Berger, J.-M. Bidart, M. Weber, A. Bristow, R. Norman, C. Sturgeon, and U.-H. Stenman Preparation and Characterization of New WHO Reference Reagents for Human Chorionic Gonadotropin and Metabolites Clin. Chem., January 1, 2003; 49(1): 144 - 154. [Abstract] [Full Text] [PDF]

				F. M. Reis, D. D'Antona, and F. Petraglia Predictive Value of Hormone Measurements in Maternal and Fetal Complications of Pregnancy Endocr. Rev., April 1, 2002; 23(2): 230 - 257. [Abstract] [Full Text] [PDF]

				P. Mock, G. Kovalevskaya, J. F. O'Connor, and A. Campana Choriocarcinoma-like human chorionic gonadotrophin (HCG) and HCG bioactivity during the first trimester of pregnancy Hum. Reprod., October 1, 2000; 15(10): 2209 - 2214. [Abstract] [Full Text] [PDF]

				G. Kovalevskaya, S. Birken, T. Kakuma, J. Schlatterer, and J. F. O'Connor Evaluation of Nicked Human Chorionic Gonadotropin Content in Clinical Specimens by a Specific Immunometric Assay Clin. Chem., January 1, 1999; 45(1): 68 - 77. [Abstract] [Full Text] [PDF]

				L. A. Cole Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites Clin. Chem., December 1, 1997; 43(12): 2233 - 2243. [Abstract] [Full Text] [PDF]

				S.-B. Hu, L. Johnson, P. C. Roche, and H. T. Keutmann A Functional Determinant in Human Luteinizing Hormone and Chorionic Gonadotropin: Differential Effect of Mutations about {beta}-GLN-54 Endocrinology, April 1, 1997; 138(4): 1627 - 1633. [Abstract] [Full Text] [PDF]